JDRF invests in single-port CGM and insulin infusion set

The type 1 diabetes charity JDRF has announced a new partnership with Pacific Diabetes Technologies (PDT) that will support the development of novel continuous glucose monitor (CGM) infusion set.
CGMs can improve blood sugar control in both type 1 and type 2 diabetes, which work for 24 hours a day and can include alarms to indicate when your blood glucose levels are too high or too low.
As part of this new collaboratio, JDRF will pay PDT $1.14m to fund the development of an advanced infusion set that combines a CGM and insulin infusion into a single device.
PDT, which is based in Portland, Orego, US calls this device a “single-port” CGM solution, which enables users to monitor blood glucose levels from the same device that delivers insulin, rather than having to wear two separate devices.
The medical device company has already begun testing prototypes in animal studies and is working towards obtaining FDA approval.
“This investment will allow PDT to continue development of our novel glucose monitoring infusion set,” said Robert Cargill, president and CEO of PDT.
“This JDRF funding provides critical support as we move our technology into human feasibility trials and prepare our products for market.”
The funds invested by JDRF will be distributed as a series of milestone payments, will help PDT refine the device in preparation for market.
Vincent Crabtree, director of Research Business Development at JDRF, added: “JDRF is excited to partner with Pacific Diabetes Technologies to help advance infusion set technology that could improve the lives of people living with type 1 diabetes.
“The T1D community is looking forward to advances in their CGM devices that can improve their ability to maintain glucose control safely and conveniently, and JDRF is committed to enabling that type of next-generation technology.”